Form 4: Envoy Medical Director Charles Brynelsen Boosts Stake with Significant Stock Purchases

Envoy Medical, Inc. Director Charles Brynelsen has increased his direct ownership in the company by acquiring 50,000 shares of Class A Common Stock through open market purchases in late May 2025.

Summary

• Charles Brynelsen, a Director of Envoy Medical, Inc. (COCH), reported multiple open market purchases of Class A Common Stock.
• On May 22, 2025, Mr. Brynelsen purchased 2,000 shares at a weighted average price of $1.6834 per share, bringing his direct ownership to 2,000 shares.
• On May 23, 2025, an additional 13,000 shares were acquired at a weighted average price of $1.6433 per share, increasing his direct holdings to 15,000 shares.
• On May 27, 2025, Mr. Brynelsen purchased 35,000 shares at a weighted average price of $1.6478 per share, resulting in a total direct beneficial ownership of 50,000 Class A Common Stock shares.
• The reported prices are weighted averages, with purchases occurring within specified price ranges for each transaction.
• Mr. Brynelsen also holds 62,500 stock options to purchase Class A Common Stock at an exercise price of $2.4, which expire on October 15, 2033.
• Of these options, 46,875 shares vested on October 15, 2023, with the remaining 15,625 shares vesting pro rata monthly over 36 consecutive months thereafter.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant increase in direct beneficial ownership by a company director through open market purchases, indicating strong insider confidence.

Positives

• A Director, Charles Brynelsen, significantly increased his direct ownership in Envoy Medical, Inc. by purchasing 50,000 shares, signaling strong insider confidence in the company's future prospects.
• The purchases were made on the open market, indicating a voluntary investment decision by the insider.
• The director's total direct beneficial ownership of Class A Common Stock now stands at 50,000 shares, demonstrating a substantial personal stake.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook. It solely reports insider trading activity.

Industry Context

This insider transaction reflects a director's individual investment decision within the medical device industry. While not indicative of broader industry trends, significant insider buying can sometimes signal internal optimism about a company's specific market position or upcoming developments.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive indicator of the company's future performance and a sign of alignment between management and shareholder interests.

Next Steps

• The remaining 15,625 stock options held by Charles Brynelsen will continue to vest pro rata on the 15th of each month for 36 consecutive months following October 15, 2023.

Key Dates

Recommendation

Keywords

Envoy Medical, COCH, Insider Trading, Form 4, Stock Purchase, Director, Beneficial Ownership, Equity Acquisition, Medical Devices